Back to search

Article

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer

2025-07-19

Abstract excerpt

<h4>Summary</h4> Treatment options and diagnostic outlook for men with advanced, therapy resistant prostate cancer (PCa) are extremely poor; this is primarily due to the common lack of durable response to androgen receptor (AR) targeted therapies and phenotypic transdifferentiation into a particularly lethal subtype known as neuroendocrine prostate cancer (NEPC). In this study, we mechanistically determine that S...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5611efe8-a91a-564a-abb4-088b70963769
DOI
10.1101/2025.07.18.664790
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancerDOI 10.1101/2025.07.18.664790
Select a neighboring publication to make it the new centre.